U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8 - K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 26, 1998
BSD MEDICAL CORPORATION
Commission file number 0-10783
DELAWARE 75-1590407
(State of Incorporation) (IRS Employer Identification Number)
2188 West 2200 South
Salt Lake City, Utah 84119
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 972-5555
<PAGE>
CURRENT EVENTS ON FORM 8-K
ITEM 5. OTHER EVENTS
On May 26, 1998, the attached press release was issued
regarding a joint settlement agreement between Urologix, Inc.,
BSD Medical Corporation and TherMatrx, Inc.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits:
No exhibits are being filed with this Form 8-K.
<PAGE>
For Immediate Release
Urologix, Inc., BSD Medical Corp., and TherMatrx, Inc.
Jointly Announce Settlement Agreement
MINNEAPOLIS, SALT LAKE CITY, and LAKE FOREST, Ill., May 26,
1998 -- Urologix, Inc. (Nasdaq: ULGX); BSD Medical Corporation
(OTCBB: BSDM); and TherMatrx, Inc. jointly announced today
that they have entered into a Settlement Agreement resolving
their current litigation, entitled Urologix, Inc. v. BSD
Medical Corporation, et al., Case No. 4-96-647.
Pursuant to the Settlement Agreement, Urologix has paid BSD
and TherMatrx a total of $5 million, the parties have executed
mutual releases, and the parties have jointly filed a Notice
of Dismissal With Prejudice of the pending litigation. Under
the terms of the Settlement, Urologix will maintain its non-
exclusive license to certain patents owned by TherMatrx and
BSD pertaining to transurethral insertable applicators and
systems for the treatment of benign prostatic hyperplasia
(BPH) and other urological conditions. The non-exclusive
license is now fully paid-up, irrevocable, perpetual, non-
cancelable, and non-terminable under all circumstances.
Urologix, Inc., based in Minneapolis, develops, manufactures
and markets minimally invasive medical devices for the
treatment of urological diseases. BSD Medical Corporation,
based in Salt Lake City, Utah, is the leading developer and
manufacturer of hyperthermia systems for cancer therapy.
TherMatrx, Inc., a Delaware corporation headquartered in Lake
Forest, Illinois, was formed by BSD and Oracle Strategic
Partners, L.P. of New York, N.Y. in November of 1997 to focus
on minimally invasive treatments of urological diseases,
specifically benign prostatic hyperplasia (BPH).
Statements contained in this press release which are not
historical facts are forward looking statements as that item
is defined in the Private Securities Litigation Reform Act of
1995. Such forward-looking statements are subject to risks
and uncertainties which could cause actual results to differ
materially from estimated results. Such risks and
uncertainties are detailed in the Company's filings with the
Securities and Exchange Commission.
######
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly
authorized.
BSD MEDICAL CORPORATION
Date: June 4, 1998 By: /s/ Paul F. Turner
Paul F. Turner
Chairman of the Board, Acting
President, and Senior Vice
President of Research
